Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase.

被引：0
|
作者：
Druker, BJ
Gathmann, I
Bolton, AE
Larson, RA
机构：
[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR USA
[2] Novartis Pharma, Basel, Switzerland
[3] Univ Chicago, Chicago, IL 60637 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
634
引用
收藏
页码：182A / 182A
页数：1
相关论文
共 50 条
  • [21] Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
    Linga, Vijay Gandhi
    Ganta, Ranga Raman
    Kalpathi, Krishnamani Iyer
    Gundeti, Sadashivudu
    Rajappa, Senthil J.
    Digumarti, Raghunadharao
    Paul, Tara Roshni
    Tandon, Ashwani
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (04) : 203 - 205
  • [22] Response to imatinib mesylate in late chronic phase chronic myeloid leukemia
    Mukhopadhyay, S.
    Chitalkar, P. G.
    Gupta, P. R.
    Roy, U.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 41
  • [23] Complete cytogenetic response to cytarabine-containing chemotherapy and imatinib mesylate in a patient with acute blastic phase of chronic myeloid leukemia (CML).
    Kalla, H
    Lerma, P
    Besa, EC
    BLOOD, 2003, 102 (11) : 250B - 251B
  • [24] Darbepoetin alfa (Aranesp™) for anemia during imatinib mesylate (Gleevec™) therapy for chronic phase chronic myeloid leukemia (CML).
    Quintas-Cardama, A
    Ault, P
    Kantarjian, H
    O'Brien, S
    Cabanillas, M
    Rios, MB
    Verstovsek, S
    Talpaz, M
    Cortes, J
    BLOOD, 2003, 102 (11) : 312B - 312B
  • [25] VARIANT PH TRANSLOCATION IN EARLY CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA: CYTOGENETIC - MOLECULAR CHARACTERIZATION AND CORRELATION TO IMATINIB MESYLATE THERAPY (A GIMEMA WP ON CML ANALYSIS)
    Marzocchi, G.
    Luatti, S.
    Castagnatti, F.
    Baldazzi, C.
    Stacchini, M.
    Gamberini, C.
    Amabile, M.
    Soverini, S.
    Colarossi, S.
    Specchia, G.
    Sessarego, M.
    Giussani, U.
    Zanatta, L.
    Valori, L.
    Discepoli, G.
    Montaldi, A.
    Santoro, A.
    Sebastio, L.
    Giudici, G.
    Bonaldi, L.
    Cianciulli, A.
    Giacobbi, F.
    Palandri, F.
    Rosti, G.
    Baccarani, M.
    Testoni, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 333 - 333
  • [26] BUSULFAN, AND NOT DURATION OF DISEASE, RESULTS IN DECREASE OF RESPONSE TO IMATINIB IN VERY LATE CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA (CML)
    Zaritskey, A.
    Martinkevich, I.
    Shuvaev, V.
    Abdulkadyrova, A.
    Udalieva, V.
    Usacheva, E.
    Shikhbabava, D.
    Golubeva, M.
    Meresii, S.
    Machulaitene, E.
    Zotova, I.
    Poznyak, E.
    Koryagina, E.
    Ilina, N.
    Shneider, T.
    Romanova, E.
    Salamatova, E.
    Lazorko, N.
    Lomaia, E.
    Abdulkadyrov, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 544 - 544
  • [27] CYTOGENETIC STAGING OF CHRONIC MYELOID-LEUKEMIA (CML)
    SANDBERG, AA
    BOLLETTINO DELL ISTITUTO SIEROTERAPICO MILANESE, 1978, 57 (03): : 247 - 256
  • [28] Weight gain associated with imatinib therapy in patients with chronic myeloid leukemia (CML).
    Ault, P
    Kantarjian, H
    Kaled, S
    Rios, MB
    O'Brien, S
    Cortes, JE
    BLOOD, 2002, 100 (11) : 321B - 321B
  • [29] The impact of cytogenetic clonal evolution (CgCE) on the therapeutic response (hematologic and cytogenetic response rates) to imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML) Ph+
    Vargas-Viveros, P
    Hurtado-Monroy, R
    Cervera-Ceballos, E
    Viana-Alvarez, RM
    Rodriguez-Zulueta, P
    BLOOD, 2003, 102 (11) : 320B - 320B
  • [30] Imatinib therapy in chronic myeloid leukemia
    Crossman, LC
    O'Brien, SG
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (03) : 605 - +
12345